Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study

Yong Yang, Ying Wang, Xin Liu, Xia He, Li Ling Zhang, Gang Wu, Bao Lin Qu, Li Ting Qian, Xiao Rong Hou, Fu Quan Zhang, Xue Ying Qiao, Hua Wang, Gao Feng Li, Yuan Zhu, Jian Zhong Cao, Jun Xin Wu, Tao Wu, Su Yu Zhu, Mei Shi, Li Ming XuHang Su, Yu Qin Song, Jun Zhu, Yu Jing Zhang, Hui Qiang Huang, Chen Hu, Shu Nan Qi, Ye Xiong Li

Research output: Contribution to journalArticlepeer-review

Abstract

Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of extranodal NK/T-cell lymphoma (ENKTCL) in the modern era. We aim to analyze progression-free survival at 24 months (PFS24) and subsequent overall survival (OS) in a large-scale multicenter cohort of patients. 1790 patients were included from the China Lymphoma Collaborative Group (CLCG) database. Subsequent OS was defined from the time of PFS24 or progression within 24 months to death. OS was compared with age- and sex-matched general Chinese population using expected survival and standardized mortality ratio (SMR). Patients who did not achieve PFS24 had a median OS of 5.3 months after progression, with 5-year OS rate of 19.2% and the SMR of 71.4 (95% CI, 62.9–81.1). In contrast, 74% patients achieved PFS24, and the SMR after achieving PFS24 was 1.77 (95% CI, 1.34–2.34). The observed OS rate after PFS24 versus expected OS rate at 5 years was 92.2% versus 94.3%. Similarly, superior outcomes following PFS24 were observed in early-stage patients (5-year OS rate, 92.9%). Patients achieving PFS24 had excellent outcome, whereas patients exhibiting earlier progression had a poor survival. These marked differences suggest that PFS24 may be used for study design and risk stratification in ENKTCL.

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study'. Together they form a unique fingerprint.

Cite this